{"disease":{"id":"viral","name":"viral"},"drugs":{"marketed":[{"drug_id":"elvitegravir","indication_name":"Replacement of Current Antiretroviral Regimen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitekta","generic_name":"ELVITEGRAVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Vitekta blocks the integrase enzyme, preventing HIV from replicating."},{"drug_id":"interferon-alfa-2b","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intron A","generic_name":"INTERFERON ALFA-2B","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Interferon alpha","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lamivudine","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epivir","generic_name":"LAMIVUDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Deoxycytidine kinase","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":66,"revenue":null,"mechanism":"Epivir works by mimicking the building blocks of DNA to prevent the replication of viral genetic material."},{"drug_id":"adefovir-dipivoxil","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hepsera","generic_name":"ADEFOVIR DIPIVOXIL","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"DNA polymerase subunit gamma-1","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":64,"revenue":null,"mechanism":"Hepsera works by mimicking a building block of DNA, which it uses to trick the Hepatitis B Virus into incorporating faulty genetic material, ultimately halting its replication."},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"peginterferon","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Peginterferon","company_name":"Ziv Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"viread","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Viread","company_name":"Replicor Inc.","drug_phase":"marketed","molecular_target":"Gag-Pol polyprotein, Reverse transcriptase/RNaseH","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"pegasys","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pegasys","company_name":"Zealand University Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"clevudine","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levovir","generic_name":"CLEVUDINE","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"clevudine","quality_score":null,"revenue":null,"mechanism":"Levovir works by inhibiting viral DNA synthesis, specifically targeting the hepatitis B virus."},{"drug_id":"adefovir","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ADEFOVIR","company_name":"","drug_phase":"discontinued","molecular_target":"DNA polymerase subunit gamma-1, Capsid protein, Protein P","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Adefovir is an antiviral medication used to treat chronic hepatitis B in adults and adolescents, with common side effects including fatigue, headache, and stomach pain."},{"drug_id":"tesamorelin-acetate","indication_name":"Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Egrifta","generic_name":"TESAMORELIN ACETATE","company_name":"Theratechnologies","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"Growth Hormone Releasing Factor Analog","quality_score":10,"revenue":null,"mechanism":"Egrifta works by mimicking the action of growth hormone-releasing hormone to stimulate the release of growth hormone."},{"drug_id":"sebivo","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sebivo","company_name":"Ziv Hospital","drug_phase":"phase_1","molecular_target":"Capsid protein, Protein P","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"baraclude","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Baraclude","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Capsid protein, Protein P, Protein P","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of viral conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"entecavir","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baraclude","generic_name":"ENTECAVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"entecavir","quality_score":70,"revenue":null,"mechanism":"Entecavir works by inhibiting the replication of the hepatitis B virus."},{"drug_id":"vaccination","indication_name":"viral-related symptoms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Post - Vaccination","generic_name":"vaccination","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"Inactivated Poliovirus Vaccine [EPC]","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"bulevirtide","indication_name":"Chronic viral hepatitis B with hepatitis D","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hepcludex","generic_name":"BULEVIRTIDE","company_name":"MYR GmbH","drug_phase":"marketed","molecular_target":"Sodium/bile acid cotransporter","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"Cytomegaloviral retinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"fomivirsen","indication_name":"Cytomegaloviral retinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FOMIVIRSEN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"fomivirsen","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"hepsera","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hepsera","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"DNA polymerase subunit gamma-1, Capsid protein, Protein P","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"peginterferon-alfa-2a","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pegasys","generic_name":"PEGINTERFERON ALFA-2A","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":83,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05321433","title":"Tobacco Use and the Risk of COVID-19 and Adverse Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":757585,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04256395","title":"Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":102456,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT04914832","title":"Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":75012,"lead_sponsor_name":"Shabir Madhi","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT04624048","title":"Exercise Influence on COVID-19","phase":"","overall_status":"UNKNOWN","enrollment_count":30000,"lead_sponsor_name":"University of Salamanca","has_results":false},{"nct_id":"NCT04532411","title":"COVID-19 Testing Sample Acquisition Throughput and Efficiency","phase":"","overall_status":"COMPLETED","enrollment_count":28948,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05620953","title":"Severe Acute Respiratory Infections (SARI) in Belgium (2011-2020)","phase":"","overall_status":"COMPLETED","enrollment_count":12145,"lead_sponsor_name":"Sciensano","has_results":false},{"nct_id":"NCT04330261","title":"Clinical Characteristics and Outcomes of Pediatric COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":10610,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT04623047","title":"Infection Watch Study","phase":"","overall_status":"COMPLETED","enrollment_count":10034,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06123936","title":"Impact on Influenza Vaccination Rates of a Telephone Text Message Recall From the Attending Physician","phase":"NA","overall_status":"UNKNOWN","enrollment_count":8400,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06647797","title":"Enhancing Communication on Relationship Preservation, Safer Conception and PrEP to Promote HIV Testing in Uganda","phase":"NA","overall_status":"COMPLETED","enrollment_count":7666,"lead_sponsor_name":"Children's Mercy Hospital Kansas City","has_results":false},{"nct_id":"NCT04367740","title":"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":6313,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":false},{"nct_id":"NCT05244356","title":"Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation","phase":"NA","overall_status":"COMPLETED","enrollment_count":5784,"lead_sponsor_name":"Clinical Research Centre, Malaysia","has_results":false},{"nct_id":"NCT04898140","title":"The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents","phase":"","overall_status":"COMPLETED","enrollment_count":5340,"lead_sponsor_name":"Moscow Department of Health","has_results":false},{"nct_id":"NCT06784960","title":"Communication Strategies to Increase HPV Vaccination Intention","phase":"NA","overall_status":"COMPLETED","enrollment_count":5337,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT04245800","title":"Home Testing of Respiratory Illness","phase":"","overall_status":"COMPLETED","enrollment_count":5233,"lead_sponsor_name":"Evidation Health","has_results":false},{"nct_id":"NCT04684602","title":"Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Thomas Advanced Medical LLC","has_results":false},{"nct_id":"NCT05139524","title":"RVF and Other Emerging Infectious Diseases in East and Central Africa","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Washington State University","has_results":false},{"nct_id":"NCT07359287","title":"Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":4500,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT06800950","title":"Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":4400,"lead_sponsor_name":"Institute of Medical Biology, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06993753","title":"Duration of Protection of Nirsevimab Against Hospitalisation for Respiratory Syncytial Virus Infection","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4350,"lead_sponsor_name":"Griffith University","has_results":false},{"nct_id":"NCT04442217","title":"Factors Associated With Adherence to Hygiene-related Behaviors and Viral Mitigation Protocols During the COVID-19 Pandemic","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"University of Oslo","has_results":false},{"nct_id":"NCT05282745","title":"A Multicenter Cohort Study of HPV Viral Load in Predicting the Postoperative Recurrence of HSIL","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Fujian Maternity and Child Health Hospital","has_results":false},{"nct_id":"NCT04998344","title":"An Effectiveness Trial to Evaluate Protection of Children and Pregnant Women by Influenza Vaccine in Rural Bangladesh","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3800,"lead_sponsor_name":"University of Bergen","has_results":false},{"nct_id":"NCT06178822","title":"Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room","phase":"","overall_status":"RECRUITING","enrollment_count":3300,"lead_sponsor_name":"Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)","has_results":false},{"nct_id":"NCT05913700","title":"Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3067,"lead_sponsor_name":"Institute for Clinical Effectiveness, Japan","has_results":false},{"nct_id":"NCT04371276","title":"Seroepidemiology of Viral Hepatitis in Hong Kong","phase":"","overall_status":"COMPLETED","enrollment_count":2888,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT04344327","title":"Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF","phase":"","overall_status":"COMPLETED","enrollment_count":2878,"lead_sponsor_name":"French Cardiology Society","has_results":false},{"nct_id":"NCT05624450","title":"Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2870,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03356405","title":"Evaluating Treatment as Prevention Among People Who Inject Drugs in Dundee for HCV","phase":"","overall_status":"COMPLETED","enrollment_count":2800,"lead_sponsor_name":"University of Dundee","has_results":false},{"nct_id":"NCT03110770","title":"VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2428,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT05652400","title":"HIV Transmission in the Era of Scaling up Antiretroviral Therapy in Ethiopia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Lund University","has_results":false},{"nct_id":"NCT07177508","title":"First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory","phase":"","overall_status":"COMPLETED","enrollment_count":2355,"lead_sponsor_name":"Nicola Irwin","has_results":false},{"nct_id":"NCT00342186","title":"Genes Involved in Resistance or Susceptibility to Hepatitis B Virus","phase":"","overall_status":"COMPLETED","enrollment_count":2303,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06904820","title":"Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures \"Outside the Walls\" by Dual Screening Method RTDs and FibroScan®","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT03775798","title":"Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.","phase":"","overall_status":"UNKNOWN","enrollment_count":2200,"lead_sponsor_name":"Austral University, Argentina","has_results":false},{"nct_id":"NCT04470011","title":"Survey of Procedures and Resources for Initiating Treatment of HIV in Africa-Zambia","phase":"","overall_status":"COMPLETED","enrollment_count":2189,"lead_sponsor_name":"Boston University","has_results":false},{"nct_id":"NCT04290780","title":"COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","phase":"","overall_status":"COMPLETED","enrollment_count":2162,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04062253","title":"Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid","phase":"","overall_status":"COMPLETED","enrollment_count":2001,"lead_sponsor_name":"Hospital Universitario Infanta Leonor","has_results":false},{"nct_id":"NCT07274345","title":"Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Amira Mohamed Zidan","has_results":false},{"nct_id":"NCT05336851","title":"Emergency PWAS in Respiratory Infectious Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT05398952","title":"Post-COVID-19 Outpatient Care and Biomarkers","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT07110636","title":"Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Karius, Inc.","has_results":false},{"nct_id":"NCT03418441","title":"Central Nervous System Infections in Denmark","phase":"","overall_status":"RECRUITING","enrollment_count":1900,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT00913757","title":"A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area","phase":"","overall_status":"COMPLETED","enrollment_count":1871,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04353141","title":"International Lung UltraSound Analysis (ILUSA) Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1850,"lead_sponsor_name":"KU Leuven","has_results":false},{"nct_id":"NCT04468399","title":"Survey of Procedures and Resources for Initiating Treatment of HIV in Africa-Malawi","phase":"","overall_status":"COMPLETED","enrollment_count":1781,"lead_sponsor_name":"Boston University","has_results":false},{"nct_id":"NCT00023023","title":"Study of Transfusion-Transmitted Infections","phase":"","overall_status":"COMPLETED","enrollment_count":1771,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT04141917","title":"Test-and-treat for Influenza in Homeless Shelters","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":1618,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT02112890","title":"Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico","phase":"","overall_status":"COMPLETED","enrollment_count":1603,"lead_sponsor_name":"GlaxoSmithKline","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}